



Stabilis



Mesna



Prekinis pavadinimas

Anti Uron	Lenkija
Mecav	Meksikas
Medaltec	Meksikas
Mescryo	Meksikas
Mesna	Argentina, Čilė, Egiptas, Jungtinės Amerikos Valstijos, Kanada, Meksikas, Naujojoje Zelandijoje, Peru, Venesuela, Vokietija
Mesnex	Jungtinės Amerikos Valstijos
Mesnil	Meksikas
Mestrian	Argentina
Mexnair	Kolumbija
Neilar	Meksikas
Novacarel	Meksikas
Uromes	Egiptas, Ekvadoras, Meksikas
Uromitexan	Airija, Australija, Austrija, Belgija, Didžioji Britanija, Egiptas, Ekvadoras, Graikija, Iranas, Islandija, Ispanija, Italija, Kanada, Kolumbija, Lenkija, Liuksemburgas, Marokas, Naujojoje Zelandijoje, Norvegija, Olandija, Portugalija, Prancūzija, Rumunija, Saudo Arabija, Suomija, Švedija, Šveicarija, Tunisas, Turkija, Venesuela, Vengrija, Vokietija
Uroprot	Čilė, Kolumbija, Venesuela
Xolem	Venesuela



Mišinių stabilumas

		2 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4	
PVC		20 mg/ml	37°C		Ifosfamide : 20 mg/ml	7	
PVC		20 mg/ml	8°C		Ifosfamide : 20 mg/ml	14	
PVC		20 mg/ml	20-25°C		Ifosfamide : 20 mg/ml	14	
PVC		30 mg/ml	20-25°C		Ifosfamide : 30 mg/ml	14	

PVC		10 mg/ml	20-25°C		Ifosfamide : 10 mg/ml	14		3610
PVC		0,2 & 1 mg/ml	20°C		Cyclophosphamide : 1 mg/ml	24		2104
PVC		1 mg/ml	20°C		Cyclophosphamide : 5 mg/ml	24		2104
PVC		2 & 10 mg/ml	20°C		Cyclophosphamide : 10 mg/ml	24		2104
PVC		2 & 10 mg/ml	20°C		Ifosfamide : 10 mg/ml	48		2104
PVC		1 mg/ml	20°C		Ifosfamide : 5 mg/ml	48		2104
PVC		0,2 & 1 mg/ml	20°C		Ifosfamide : 1 mg/ml	48		2104
PE		0,54 mg/ml	22°C		Cyclophosphamide : 1,8 mg/ml	6		1833
PE		3,2 mg/ml	22°C		Cyclophosphamide : 10,8 mg/ml	24		1833
PE		3,2 mg/ml	4°C		Cyclophosphamide : 10,8 mg/ml	48		1833
PE		0,54 mg/ml	4°C		Cyclophosphamide : 1,8 mg/ml	48		1833
		40 mg/ml	4°C		Ifosfamide : 50 mg/ml	28		1317



Suderinamumas

		Mesna : 1.8 mg/ml		150
		Mesna		3602
		Mesna : 10 mg/ml		301
		Mesna : 10 mg/ml		1415
		Mesna : 10 mg/ml Allopurinol sodium : 3 mg/ml		307
		Mesna : 10 mg/ml Amifostine : 10 mg/ml		3
		Mesna Aminophylline		3602
		Mesna : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Mesna : 10 mg/ml Aztreonam : 40 mg/ml		99
		Mesna Carboplatin		3602
		Mesna : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Mesna : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Mesna Cisplatin		4084
		Mesna Cisplatin		3602

	Mesna : 10 mg/ml Cladribine : 0.5 mg/ml		1496
	Mesna : 10 mg/ml Cladribine : 0.015 mg/ml		1496
	Mesna : 3.2 mg/ml Cyclophosphamide : 10.8 mg/ml		1833
	Mesna : 0.2 >> 10 mg/ml Cyclophosphamide : 1 >> 10 mg/ml		2104
	Mesna : 0.54 mg/ml Cyclophosphamide : 1.8 mg/ml		1833
	Mesna : 4.76 mg/ml Defibrotide : 8 mg/ml		3728
	Mesna : 10 mg/ml Docetaxel : 0.9 mg/ml		1754
	Mesna : 10 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Mesna Erythromycin lactobionate		3602
	Mesna : 10 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Mesna : 10 mg/ml Filgrastim : 30 µg/ml		244
	Mesna : 10 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Mesna : 20 mg/ml Fosfomycin : 30 mg/ml		4055
	Mesna : 20 mg/ml Fosfomycin : 30 mg/ml		4055
	Mesna : 20 mg/ml Gallium nitrate : 1 mg/ml		91
	Mesna : 10 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Mesna : 4 mg/ml Granisetron hydrochloride : 1 mg/ml		57
	Mesna : 3 mg/ml Hydroxyzine dihydrochloride : 0.5 mg/ml		331
	Mesna : 10 >> 30 mg/ml Ifosfamide : 10 >> 30 mg/ml		3610
	Mesna : 0.2 >> 10 mg/ml Ifosfamide : 1 >> 10 mg/ml		2104
	Mesna : 20 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Mesna : 20 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Mesna : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Mesna : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Mesna : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Mesna : 10 mg/ml Linezolid : 2 mg/ml		1925

	Mesna : 10 mg/ml Melfalan : 0.1 mg/ml		169
	Mesna : 1.8 mg/ml Methotrexate sodium : 30 mg/ml		150
	Mesna : 20 mg/ml Micafungin : 1.5 mg/ml		2108
	Mesna : 10 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Mesna Oxaliplatin		3602
	Mesna : 10 mg/ml Oxaliplatin : 0,5 mg/ml		1662
	Mesna : 10 mg/ml Paclitaxel : 1.2 mg/ml		248
	Mesna : 10 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Mesna : 10 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Mesna : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Mesna : 10 mg/ml Sargramostim : 10 µg/ml		335
	Mesna : 1.8 mg/ml Sodium bicarbonate : 14 mg/ml		150
	Mesna : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Mesna : 20 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Mesna : 10 mg/ml Teniposide : 0.1 mg/ml		905
	Mesna : 10 mg/ml Thiotepa : 1 mg/ml		249
	Mesna : 10 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Leidimo būdai



Bibliografija

	tipas	leidinys
3	Žurnalas	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.

57	Žurnalas	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Žurnalas	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Žurnalas	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Žurnalas	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Žurnalas	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Žurnalas	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Žurnalas	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Žurnalas	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Žurnalas	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Žurnalas	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Žurnalas	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301	Žurnalas	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Žurnalas	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Žurnalas	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplastic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Žurnalas	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Žurnalas	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.

492	Žurnalas	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
905	Žurnalas	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Žurnalas	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1317	Žurnalas	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1408	Žurnalas	Priston MJ, Sewell GJ. Stability of three cytotoxic drugs infusions in the Graseby 9000 ambulatory infusion pump. J Oncol Pharm Practice 1998 ; 4: 143-149.
1410	Žurnalas	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Žurnalas	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Žurnalas	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Žurnalas	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Žurnalas	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Žurnalas	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1754	Žurnalas	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1833	Žurnalas	Menard C, Bourguignon C, Schlatter J, Vermerie N. Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. Ann Pharmacotherapy 2003 ; 37, 12: 1789-1792.
1925	Žurnalas	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Žurnalas	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2104	Žurnalas	Iriarte Izura MA, Gozalo garcia MJ, Marcotegui Ros F, Nagore Indurain C, Urdaniz Baztan AO. Estudio de la estabilidad de mezclas ciclofosfamida/mesna e ifosfamida/mesna en soluciones intravenosas de gran volumen. Farm Hosp 2000 ; 24: 145-150

2108	Žurnalas	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
3602	Laboratorija	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3610	Žurnalas	Zhang, Y., Kawedia, J.D., Myers, A.L., McIntyre, C.M., Anderson, P.M., Kramer, M.A., Culotta, K. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. J Oncol Pharm Practice 2014 ; 20, 1: 51-57.
3728	Žurnalas	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3827	plakatas	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakatas	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakatas	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuconazole sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Žurnalas	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomicin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4084	Laboratorija	Cisplatine - Résumé des caractéristiques du produits Accord Health Care 2017
4145	Žurnalas	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Žurnalas	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4801	Žurnalas	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Žodynas

	Citoprotekcinis vaistas		Išpurškimas
	Prekinis pavadinimas		Mišinių stabilumas
	Pakuotė		Tirpiklis
	Koncentracija		Temperatūra
	Laikymas		Molekulė
	Stabilumo trukmė		Nuorodos
	Stiklas		Natrio chloridas 0,9%
	Šviesa		Valanda
	Polivinilchloridas		Vanduo injekcijoms
	Apsaugotas nuo šviesos		Diena
	Polietilenas		Gliukozė 5%
	Nenurodyta		Švirkštas polipropileno
	Suderinamumas		Suderinamas
	NaHCO ₃		Parenterinis maitinimas (lipidų nemokamai)
	Parenteriniu būdu (su lipidų)		Nepatikslintas nesuderinamumas
	Nesuderinamas		Nedelsiant krituliai
	NaCl 0,9% + antibakterinis		Krituliai po 4 valandų
	Nėra		Leidimo būdai
	Intraveninis		Intraveninė infuzija
	Pastovi infuzija		Pastovi poodinė instiliacija
	Bibliografija		Žodynas